Spanish and European health care stocks
The official accounts of 65 Spanish and European companies in the health care sector, ranked by revenue for their latest fiscal year. Each one links to its page, with the filing behind every figure.
Of the 65 companies, 38 earned more in their latest fiscal year than in the one before; 22 closed it with a loss.
Each amount is in the currency the company reports in; the rank converts revenue to US dollars at the 16 November 2026 exchange rate.
US companies in the sector are in US health care stocks .
Spain
Rest of Europe
Rank Company Ticker Revenue Net income Net income change
1 AstraZeneca LON: AZN $58,739m $10,225m +45.3%
2 Novo Nordisk CPH: NOVO-B DKK 309,064m DKK 102,434m +1.4%
3 Philips AMS: PHIA €17,834m €895.0m —
4 Haleon LON: HLN £11,030m £1,667m +15.6%
5 emeis EPA: EMEIS €5,895m −€298.4m —
6 Smith & Nephew LON: SN $6,164m $625.0m +51.7%
7 Ramsay Générale de Santé EPA: GDS €5,381m −€48.3m —
8 Clariane EPA: CLARI €5,310m €1.6m —
9 bioMérieux EPA: BIM €4,070m €397.5m −8.0%
10 Argenx EBR: ARGX $4,151m $1,292m +55.1%
11 Coloplast CPH: COLO-B DKK 27,874m DKK 3,636m −28.0%
12 Genmab CPH: GMAB $3,720m $963.0m −15.0%
13 Getinge STO: GETI-B SEK 34,969m SEK 2,258m +37.9%
14 Demant CPH: DEMANT DKK 22,971m DKK 1,545m −35.3%
15 Hikma Pharmaceuticals LON: HIK $3,349m $402.0m +12.0%
16 Sartorius Stedim Biotech EPA: DIM €2,968m €265.6m +51.7%
17 Amplifon BIT: AMP €2,396m €91.3m −37.2%
18 Convatec Group LON: CTEC $2,439m $175.0m −8.1%
19 Spire Healthcare Group LON: SPI £1,580m £16.4m −35.4%
20 Orion HEL: ORNBV €1,890m €500.3m +51.7%
21 Zealand Pharma CPH: ZEAL DKK 9,215m DKK 6,455m —
22 DiaSorin BIT: DIA €1,195m €155.6m −17.3%
23 Safilo Group BIT: SFL €983.4m €48.6m +118.2%
24 LNA Santé EPA: LNA €912.7m €24.1m +10.7%
25 Genus LON: GNS £658.1m £285.3m +1,378.2%
26 Guerbet EPA: GBT €786.4m −€108.3m −773.5%
27 Ion Beam Applications EBR: IBAB €620.2m €12.7m +37.6%
28 EL.En. BIT: ELN €596.9m €43.4m −15.9%
29 Vetoquinol EPA: VETO €525.7m €57.4m −2.3%
30 Garofalo Health Care BIT: GHC €487.1m €23.4m +7.9%
31 Pharming Group AMS: PHARM $376.1m $2.9m —
32 Philogen BIT: PHIL €320.1m €229.7m +407.1%
33 Oxford Nanopore Technologies LON: ONT £223.9m −£145.2m —
34 Lumibird EPA: LBIRD €225.6m €14.0m +146.0%
35 Oxford Biomedica LON: OXB £168.7m −£30.1m —
36 Valneva EPA: VLA €174.7m −€115.2m —
37 Pharmanutra BIT: PHN €131.7m €20.0m +20.8%
38 EuKedos BIT: EUK €52.9m −€0.7m —
39 Nanobiotix EPA: NANO €29.6m −€24.0m —
40 MedinCell EPA: MEDCL €24.3m −€31.3m —
41 ArcticZymes Technologies OSL: AZT NOK 112.6m NOK 9.7m +15.0%
42 Hyloris Pharmaceuticals EBR: HYL €7.2m −€6.3m —
43 Onward Medical EBR: ONWD €5.4m −€41.8m —
44 Inventiva EPA: IVA €4.5m −€354.1m —
45 ABIONYX Pharma EPA: ABNX €4.1m −€5.6m —
46 OSE Immunotherapeutics EPA: OSE €2.6m −€37.7m −200.7%
47 Adocia EPA: ADOC €1.5m −€16.6m —
48 Transgene EPA: TNG €0.1m −€37.5m —
49 Aqua Bio Technology OSL: ABTEC NOK 1.3m NOK 97.7m —
50 Carvolix EPA: CVX €0.0m −€25.0m —
And 6 more: Abivax · DBV Technologies · Euroapi · GSK · Sanofi · Syncona .
Other sectors
Information technology · Financials · Consumer discretionary · Industrials · Communication services · Consumer staples · Energy · Materials · Utilities · Real estate
See all company pages →
Compare the sector in Celsmar
Inside the platform you can screen the whole sector by margins, debt or growth, and open each company's accounts line by line.
Open Celsmar →
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell.